Predictors of clinical outcomes in patients given carvedilol for heart failure

被引:4
|
作者
Greenberg, Barry
Lottes, Sandra R.
Nelson, Jeanenne J.
Lukas, Mary Ann
Fowler, Michael B.
Massie, Barry M.
Abraham, William T.
Gilbert, Edward M.
Franciosa, Joseph A. [1 ]
机构
[1] Cornell Univ, Mt Sinai Sch Med, New York, NY USA
[2] Cornell Univ, Weill Med Coll, New York, NY USA
[3] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[4] GlaxoSmithKline, Philadelphia, PA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[7] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Ohio State Univ, Sch Med, Columbus, OH 43210 USA
[10] Univ Utah, Med Ctr, Salt Lake City, UT 84112 USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2006年 / 98卷 / 11期
关键词
D O I
10.1016/j.amjcard.2006.06.050
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Risk factors for outcomes in heart failure (HF) were derived from populations in clinical trials, at hospital discharge, or in localized geographic or socioeconomic strata before the widespread use of beta blockers. This study observed 4,280 patients in a community-based HF registry for 1 year after completing carvedilol titration. Independent risk factors for death, hospitalization for HF, or hospitalization for cardiovascular reasons other than HF were first identified by age-, gender-, and race-adjusted analyses, then by multivariate analysis adjusted simultaneously for all factors. Over this period, 7% of patients died, 11% were hospitalized for HF, 12% were hospitalized for other cardiovascular reasons, and 27% had >= 1 of these events. The most significant outcome predictors were New York Heart Association class III or IV, history of hospitalization for HF or other cardiovascular reasons, and angina pectoris, all associated with increased odds of having an adverse outcome (all p <= 0.001). The left ventricular ejection fraction was not a significant outcome predictor by multivariate analysis. The odds ratio for an adverse outcome was significantly reduced for patients with hypertensive or idiopathic causes of HF and for those whose physicians had graduated from medical school >= 24 years earlier compared with < 14 years,earlier (all p < 0.005). In conclusion, easily obtained historical information predicts clinical outcomes in patients with HF in the year after initiating carvedilol. In this unselected community population, these historical factors were better predictors of risk than the left ventricular ejection fraction. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1480 / 1484
页数:5
相关论文
共 50 条
  • [31] Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice
    Massie, Barry M.
    Nelson, Jeanenne J.
    Lukas, Mary Ann
    Greenberg, Barry
    Fowler, Michael B.
    Gilbert, Edward M.
    Abraham, William T.
    Lottes, Sandra R.
    Franciosa, Joseph A.
    AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (09): : 1263 - 1268
  • [32] Tolerability of carvedilol in heart failure: Clinical trials experience
    Krum, H
    AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (9A): : 58B - 63B
  • [33] Carvedilol for heart failure
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 1997, 39 (1010): : 89 - 91
  • [34] Effect of Carvedilol on Heart Failure in Patients With a Functionally Univentricular Heart
    Ishibashi, Naoko
    Park, In-Sam
    Waragai, Tadashi
    Yoshikawa, Tadahiro
    Murakami, Yasuo
    Mori, Katsuhiko
    Mimori, Shigekazu
    Ando, Makoto
    Takahashi, Yukihiro
    Doi, Shouzaburo
    Mizutani, Shuuki
    Nakanishi, Toshio
    CIRCULATION JOURNAL, 2011, 75 (06) : 1394 - 1399
  • [35] Clinical characteristics, predictors, and outcomes of heart failure with improved ejection fraction
    Su, Kangkang
    Li, Mingquan
    Wang, Lili
    Tian, Shipeng
    Su, Jingjing
    Gu, Jian
    Chen, Shuxia
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 357 : 72 - 80
  • [36] Metoprolol and carvedilol:: pharmacological differences and their impact on the clinical use in patients with chronic heart failure
    Maack, C
    Kindermann, M
    Böhm, M
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 325 - 325
  • [37] Clinical outcomes, predictors and prognostic impact of acute heart failure in patients with ST elevation myocardial infarction
    Chamtouri, Ikram
    Amdouni, N. A.
    Jomaa, W. J.
    Ben Hamda, K. B. H.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 72 - 72
  • [38] Clinical characteristics, predictors, and outcomes of super-responder in cardiac resynchronization therapy of patients with heart failure
    Oh, J. Jaewon
    Uhm, J. S.
    Kim, I. C.
    Kim, T. H.
    Pak, H. N.
    Lee, M. H.
    Joung, B.
    Kang, S. M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2017, 19 : 459 - 459
  • [39] Carvedilol in the treatment of elderly patients with chronic heart failure
    Witte, Klaus K. A.
    Clark, Andrew L.
    CLINICAL INTERVENTIONS IN AGING, 2008, 3 (01) : 55 - 70
  • [40] Population pharmacokinetics of carvedilol in patients with congestive heart failure
    Nikolic, Valentina N.
    Jankovic, Slobodan M.
    Velickovic-Radovanovic, Radmila
    Apostolovic, Svetlana
    Stanojevic, Dragana
    Zivanovic, Slavoljub
    Stefanovic, Nikola
    Pesic, Srdjan
    Jevtovic-Stoimenov, Tatjana
    Djuric, Janko
    Markovic, Veroljub
    Milovanovic, Jasmina R.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (08) : 2851 - 2858